Anti-TIGIT antibodies

1. An antibody or antigen binding fragment thereof that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain variable region CDR1, a heavy chain variable region CDR2, and a heavy chain variable region CDR3, and the light chain variable region comprises a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3; and wherein the antibody or antigen binding fragment thereof is selected from the group consisting of:

a. an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 45, 46, or 47, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 57, 58, 59, 60, 61, or 62; and

b. an antibody or antigen binding fragment thereof comprising: a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:18, 81, 82, 83, 84, 85, 86, 87, or 88, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3, 45, 46, or 47, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:4, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:5, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:6, 57, 58, 59, 60, 61, or 62.

3. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 18, 81, 82, 83, 84, 85, 86, 87, or 88, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22.

4. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody binds to human TIGIT with a KD value of about 1×10 −9 M to about 1×10 −12 M as determined by surface plasmon resonance.

5. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody is a humanized antibody comprising two heavy chains and two light chains.

6. The antibody or antigen binding fragment thereof of claim 5 , wherein the humanized antibody comprises a human IgG1 constant domain and a human kappa constant domain.

7. The antibody or antigen binding fragment thereof of claim 1 , light chain, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, and 28, and wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30, 31, and 32.

8. The antibody or antigen binding fragment thereof of claim 7 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 26, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 30.

9. The antibody or antigen binding fragment thereof of claim 7 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 27, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 31.

10. The antibody or antigen binding fragment thereof of claim 7 , wherein the heavy chain variable region comprises is the amino acid sequence of SEQ ID NO: 28, and wherein the light chain variable region comprises is the amino acid sequence of SEQ ID NO: 32.

11. The antibody or antigen binding fragment thereof of claim 9 , wherein the antibody comprises two heavy chains and two light chains.

12. The antibody or antigen binding fragment thereof of claim 3 , wherein the antibody comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 18, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22.

13. A composition comprising the antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier or diluent.

14. The composition of claim 13 , further comprising an agent selected from the group consisting of:

a. an anti-PD1 antibody or an antigen binding fragment thereof;

b. an anti-LAG3 antibody or an antigen binding fragment thereof;

c. an anti-VISTA antibody or an antigen binding fragment thereof;

d. an anti-BTLA antibody or an antigen binding fragment thereof;

e. an anti-TIM3 antibody or an antigen binding fragment thereof;

f. an anti-CTLA4 antibody or an antigen binding fragment thereof;

g. an anti-HVEM antibody or an antigen binding fragment thereof;

h. an anti-CD27 antibody or an antigen binding fragment thereof;

i. an anti-CD137 antibody or an antigen binding fragment thereof;

j. an anti-OX40 antibody or an antigen binding fragment thereof;

k. an anti-CD28 antibody or an antigen binding fragment thereof;

l. an anti-PDL1 antibody or an antigen binding fragment thereof;

m. an anti-PDL2 antibody or an antigen binding fragment thereof;

n. an anti-GITR antibody or an antigen binding fragment thereof;

o. an anti-ICOS antibody or an antigen binding fragment thereof;

p. an anti-SIRPα antibody or an antigen binding fragment thereof;

q. an anti-ILT2 antibody or an antigen binding fragment thereof;

r. an anti-ILT3 antibody or an antigen binding fragment thereof;

s. an anti-ILT4 antibody or an antigen binding fragment thereof; and

t. an anti-ILT5 antibody or an antigen binding fragment thereof.

15. The composition of claim 14 , wherein the anti-PD1 antibody or an antigen binding fragment thereof is selected from the group consisting of: pembrolizumab or an antigen binding fragment thereof and nivolumab or an antigen binding fragment thereof.

16. The composition of claim 15 , wherein the anti-PD1 antibody is pembrolizumab.

17. An antibody or antigen binding fragment thereof that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT) comprising a light chain immunoglobulin, a heavy chain immunoglobulin or both a light chain and a heavy chain immunoglobulin, selected from the group consisting of:

a. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:8;

b. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:13;

c. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:24;

d. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 25 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:29;

e. an antibody or antigen binding fragment thereof comprising a heavy chain variable region selected from the group consisting of SEQ ID NOs: 10, 11, 12, 48, 49, 50, 51, 52, 53, 54, 55, and 56 and a light chain variable region selected from the group consisting of SEQ ID NOs: 14, 15, 16, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, and 80;

f. an antibody or antigen binding fragment thereof comprising a heavy chain variable region selected from the group consisting of SEQ ID NOs: 26, 27, 28, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, and 112 and a light chain variable region selected from the group consisting of SEQ ID NOs: 30, 31, and 32;

g. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 10, 11, 12, 48, 49, 50, 51, 52, 53, 54, 55, or 56 and a light chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 14, 15, 16, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80;

h. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 26, 27, 28, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, or 112 and a light chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 30, 31, or 32;

i. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 10, 11, 12, 48, 49, 50, 51, 52, 53, 54, 55, or 56 and a light chain variable region comprising at least 90%, 95%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 14, 15, 16, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80, wherein any sequence variations occur in the framework regions of the antibody; and

j. an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising at least 90%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 26, 27, 28, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, or 112 and a light chain variable region comprising at least 90%, 95%, 95%, 96%, 97%, 98% or 99% identity to any one of SEQ ID NOs: 30, 32, or 32, wherein any sequence variations occur in the framework regions of the antibody.

18. A humanized antibody that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody wherein the humanized antibody comprises two heavy chains and two light chains, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 27, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 31.

19. A humanized antibody that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the humanized antibody comprises a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:17, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 18, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:19, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:20, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:22, wherein the humanized antibody comprises two heavy chains and two light chains.

20. A humanized antibody that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody comprises two heavy chains and two light chains, wherein each heavy chain comprises a heavy chain variable region and each light chain comprises a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence the amino acid sequence of SEQ ID NO: 27, wherein the light chain variable region comprises the amino acid sequence the amino acid sequence of SEQ ID NO: 31, wherein the antibody comprises a human IgG1 constant domain comprising the amino acid sequence of SEQ ID NO: 44 and a human kappa constant domain comprising the amino acid sequence of SEQ ID NO: 43.

21. A humanized antibody that binds to human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody comprises two heavy chains and two light chains, wherein each heavy chain comprises a heavy chain variable region and each light chain comprises a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence the amino acid sequence of SEQ ID NO: 27, wherein the light chain variable region comprises the amino acid sequence the amino acid sequence of SEQ ID NO: 31, wherein the antibody comprises a human IgG4 constant domain comprising the amino acid sequence of SEQ ID NO: 42 and a human kappa constant domain comprising the amino acid sequence of SEQ ID NO: 43.

22. A method for detecting the presence of a T cell immunoreceptor with Ig and ITIM domains (TIGIT) peptide or a fragment thereof in a sample comprising contacting the sample with the antibody or the antigen binding fragment thereof of claim 1 and detecting the presence of a complex between the antibody or the antigen binding fragment thereof and the peptide or the fragment thereof; wherein detection of the complex indicates the presence of the TIGIT peptide or a fragment thereof.